Hosted on MSN7h
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
FierceBiotech8h
Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
FiercePharma1d
Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Are Investors Being Too Paranoid About Pfizer Stock?
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
BioSpace1d
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
MM&M2d
The Escalator: Pfizer, Vertex Pharmaceuticals, Inizio and more
Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.
Pfizer Receives Expanded FDA Approval for Cancer Treatment
The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.
BioSpace2d
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...
Contract Pharma3d
Alloy Partners with Pfizer to Develop New Antibody Discovery Platform
Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...